Mir-29 expression in the cervical epithelium in cervical intraepithelial neoplasias


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To investigate mir-29b expression levels in the cervical epithelium in cervical intraepithelial neoplasias. Subjects and methods. The investigation included 74 reproductive-aged women making up 3 groups: 1) 24 patients diagnosed with low-grade squamous intraepithelial lesions (LSIL); 2) 20 women with high-grade squamous intraepithelial lesions (HSIL); 3) a control group of 30 women without pathological changes in the cervix uteri. Cytological and histological examinations, expanded colposcopy, and a real-time polymerase chain reaction (PCR) assay for the detection of human papillomavirus were used. MicroRNA expression levels were estimated by a quantitative PCR assay using TaqMan miRNA Assays (Applied Biosystems). Results. There were 2.2- and 4.2-fold reductions in mir-29b expression levels in LSIL and HSIL (p = 0.008 and 0.0002, respectively). Estimation of mir-29b expression allows prediction of cervical intraepithelial neoplasia with a sensitivity of 70% and a specificity of 72.2%. The diagnostic efficiency was 70.3%. Conclusion. The performed investigation along with traditional studies permits consideration of mir-29b as one of the informative molecular markers to predict the degree of cervical epithelial lesion in neoplastic diseases of the cervix uteri.

Full Text

Restricted Access

About the authors

Leonid Zakievich Faizullin

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: l_faizullin@oparina4.ru
MD, Molecular-genetic Laboratory Researcher

Vitaliy Nikolaevich Karnaukhov

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: v_karnauhov@oparina4.ru
junior researcher of Molecular-genetic Laboratory

Gyuldana Raufovna Bairamova

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: g_bairamova@oparina4.ru
MD, PhD, Head of the Polyclinic Department on clinical work

Viktoriya Fedorovna Chernova

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

PhD student

Guranda Merabovna Mzarelua

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: mzareluag@mail.ru
PhD student

A. A Chausov

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: a_chausov@oparina4.ru
MD, Junior Researcher, Department of medical and social research of scientific and organizational support

Niso Mirzoevna Nazarova

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: n_nazarova@oparina4.ru
MD, PhD, Senior Researcher

Dmitriy Yur’evich Trofimov

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: d_troflmov@oparina4.ru
MD, PhD, Molecular-genetic Laboratory Chief

References

  1. Прилепская В.Н., Коган Е.А., Трофимов Д.Ю. Возможности диагностики и лечения заболеваний шейки матки. Акушерство и гинекология. 2013; 9: 90-6. [Prilepskaya V.N., Kogan E.A., Trofimov D.Yu. Possibilities of the diagnosis and treatment of the cervix uteri. Akusherstvo i ginekologiya/Obstetrics and Gynecology. 2013; 9: 90-6. (in Russian)]
  2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013; 63(1): 11-30.
  3. Waggoner S.E. Cervical cancer. Lancet. 2003; 361(9376): 2217-25. doi: 10.1016/S0140-6736(03)13778-6.
  4. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990; 63(6): 1129-36.
  5. Roman A., Munger K. The papillomavirus E7 proteins. Virology. 2013; 445(1-2): 138-68.
  6. Palmero E.I., de Campos S.G., Campos M., de Souza N.C., Guerreiro I.D., Carvalho A.L., Marques M.M. Mechanisms and role of microRNA deregulation in cancer onset and progression. Genet. Mol. Biol. 2011; 34(3): 363-70.
  7. Stahlhut C., Slack FJ. MicroRNAs and the cancer phenotype: profiling, signatures and clinical implications. Genome Med. 2013; 5(12): 111.
  8. Chua J.H., Armugam A., Jeyaseelan K. MicroRNAs: biogenesis, function and applications. Curr. Opin. Mol. Ther. 2009; 11(2): 189-99.
  9. Файзуллин Л.З., Карнаухов В.Н., Мзарелуа Г.М., Чернова В.Ф. Экспрессия микроРНК при цервикальной интраэпителиальной неоплазии и раке шейки матки. Акушерство и гинекология. 2015; 9: 27-32. [Faizullin L.Z., Karnaukhov V.N., Mzarelua G.M., Chernova V.F. MicroRNA expression in cervical intraepithelial neoplasia and cancer of the cervix uteri. Akusherstvo i ginekologiya/Obstetrics and Gynecology. 2015; 9: 27-32. (in Russian)]
  10. Hayes J., Peruzzi P.P., Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol. Med. 2014; 20(8): 460-9.
  11. Yan B., Guo Q., Fu F.J., Wang Z., Yin Z., Wei Y.B., Yang J.R. The role of miR-29b in cancer: regulation, function, and signaling. Onco Targets Ther. 2015; 8: 539-48.
  12. Liu H., Wang B., Lin J., Zhao L. MicroRNA-29b: an emerging player in human cancer. Asian Pac. J. Cancer Prev. 2014; 15(21): 9059-64.
  13. Mott J.L., Kobayashi S., Bronk S.F., Gores G.J. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene. 2007; 26(42): 6133-40.
  14. Park S.Y., Lee J.H., Ha M., Nam J.W., Kim V.N. miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat. Struct. Mol. Biol. 2009; 16(1): 23-9.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies